News and Announcements
Arthritis Relief Plus Completes US FDA Compliance, Receives Government Support & National News Coverage
- Published August 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ARP has developed and patented a novel technology – Acteev® with its lead product – 4Jointz®, a topical botanical cream addressing a significant unmet market need. It is commercial ready for key international markets.
FY 17 Company Achievements:
- Completed US FDA compliance, securing an OTC topical drug classification for 4Jointz
Secured Australian Government support in the first cohort at the RocketSpace LandingPad in San Francisco. - Awarded new Queensland Government Ignite grant.
- Completed production of first commercial pilot batch of 4Jointz in the USA.
- Direct to consumer online sales testing for USA market commenced at www.4jointz.com
- National and regional broadcast news coverage in Australia.
investment opportunity now on offer to accelerate USA market growth and support global market partnering activities.
ABOUT ARTHRITIS RELIEF PLUS
ARP (USA) Pty Ltd has been granted the rights to commercialize 4JOINTZ® in the USA by Arthritis Relief Plus Ltd, an Australian Biotechnology company, which has developed, patented and successfully completed clinical studies of its unique botanical topical (4JOINTZ®) for pain, stiffness and swelling associated with osteoarthritis and other joint conditions.
Company Updates
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Backed By Leading Investment Groups and Family Offices
